National Kidney Foundation

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

Retrieved on: 
星期四, 五月 9, 2024
Congress, Kidney disease, IgA nephropathy, Patient, Proteinuria, National Kidney Foundation, Kidney, ERA, Abstract, RAS, Immunoglobulin A, Syndrome, SPARTAN, NKF, Therapy, SAN, European Renal Association, British, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association (ERA) Congress in Stockholm, May 23-26, 2024.

Key Points: 
  • SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association (ERA) Congress in Stockholm, May 23-26, 2024.
  • At NKF the Company will present analyses comparing the effect of FILSPARI (sparsentan) as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus RAS inhibition in real-world use and in clinical trials in patients with IgA nephropathy (IgAN).
  • Additionally, new 48-week findings from the SPARTAN Study evaluating FILSPARI as a first-line treatment for patients with IgAN will be presented as a top-rated NKF abstract.
  • “At the NKF and ERA meetings we’re pleased to present critical analyses which demonstrate FILSPARI’s superior efficacy over historic RASi standard of care,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

Ballad Health, Niswonger Foundation Make Lifesaving Investment to Enhance Availability of Kidneys for Transplant, Reduce Costs of Care

Retrieved on: 
星期三, 五月 8, 2024
Kidney disease, University, OPOS, National Kidney Foundation, Kidney, Hope, Transplant, Hospital, Purdue University, Policy, News, Kidney failure, Blood, Partnership, Research, Friends, Indiana University Health, Patient, Dialysis, Medicine, Medicare, Kidney transplantation, Quality of life, NKF, University of Wisconsin–Madison, Health, Sepsis, Ballad Health, Dentistry

While waiting, most must rely upon expensive and invasive dialysis services to remain alive.

Key Points: 
  • While waiting, most must rely upon expensive and invasive dialysis services to remain alive.
  • The transplant was performed at Indiana University Health by Dr. Bill Goggins, Professor of Surgery at Indiana University School of Medicine.
  • “The leadership team of 34 Lives has more than 100 years of experience in transplantation, healthcare, policy and technology,” Eichorn said.
  • Ballad Health’s investment in 410 Medical and the adoption of LifeFlow at several of its hospitals has already generated positive outcomes for patients and accolades from clinical staff.

Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease

Retrieved on: 
星期三, 五月 8, 2024
Technology, Hospitals, Diabetes, Health Technology, Practice Management, Health, Pharmaceutical, General Health, Artificial Intelligence, Conditional sentence, Acos, Organization, Hospital, National Kidney Foundation, Health equity, Group purchasing organization, Diagnosis, Uncover, Partnership, Conference, Artificial intelligence, Workflow, Pharmacy, Kidney disease, CKD, Science, Patient, RWD, Physician, Premier, Medical missions, Exhibition, PAS, Algorithm, AstraZeneca, Prevalence

Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.

Key Points: 
  • Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.
  • The partnership with AstraZeneca demonstrates a commitment to implement and learn about innovative approaches to driving optimization of guideline-directed medical therapy for patients.
  • PINC AI™ Stanson AI-powered technology, including clinical decision support and real-time alerts integrated into the provider workflow, to help strategically modify provider behavior to improve CKD screening, diagnosis and care quality.
  • For example, these resources could include the CKD Care Journey Roadmap, CKD Health Equity Primer, clinical decision support documentation (algorithms) and other digitized resources.

CYNTHIA DELGADO AND NEIL POWE NAMED TO TIME100 HEALTH LIST FOR FIGHTING KIDNEY TRANSPLANT BIAS

Retrieved on: 
星期四, 五月 2, 2024
Task force, FASN, National Kidney Foundation, Filtration, Risk, Kidney failure, Health, Kidney, Cystatin C, GFR, Black, TIME, Creatinine, CKD, Organ, Patient, American Society of Nephrology, Society, MPH, Kidney transplantation, ASN, MBA, NKF, Chronic kidney disease, Pioneer, Global health, Nursing

The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.

Key Points: 
  • The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.
  • TIME included NKF/ASN Task Force co-chairs in its first-ever list of the 100 most influential people in global health.
  • Under the updated, race-free algorithm, some Black patients recently received modified times on the wait list for a kidney transplant.
  • The TIME100 Health List recognizes the world's most influential individuals in health across five categories: Innovators, Titans, Pioneers, Leaders, and Catalysts.

HEALWELL Subsidiaries, Khure Health & Pentavere Research Group, to Participate and Present at Upcoming Globally Recognized Medical Conferences

Retrieved on: 
星期三, 四月 17, 2024
Public, CPD, Real, Nephrology, Ophthalmology, AIDX, National Kidney Foundation, AI, Research, Health, AMIA, TSX, American Head, Conference, Artificial intelligence, Chronic kidney disease, Guideline, QC, Health information management, Oropharyngeal cancer, Patient, Faculty, Otorhinolaryngology, American Medical Informatics Association, NKF, Entertainment center, Knowledge

Pentavere will be presenting at the following medical conferences:

Key Points: 
  • Pentavere will be presenting at the following medical conferences:
    Canadian Retina Society Annual Meeting on May 3-5, 2024 in Montreal, QC.
  • American Medical Informatics Association (AMIA) Clinical Informatics Conference on May 21-23, 2024 in Minneapolis, MN.
  • Presenting Research: Using Artificial Intelligence to automate the extraction of staging criteria from the electronic health records of oropharyngeal cancer patients.
  • Thought leaders driving the future of healthcare delivery will explore practice-ready solutions to enhance patient experiences, reduce costs, and improve public health.

Makana™ Issued Patent in South Korea for Its Genetically-Modified TKO Pig for Use in Xenotransplantation

Retrieved on: 
星期三, 五月 1, 2024
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University, Genetics, National Kidney Foundation, Food, Kidney failure, Makana, Immunosuppression, Doctor of Philosophy, Jackson Memorial Hospital, Medicine, FACS, Organ transplantation, Patent, Massachusetts General Hospital, TKO, Patient, MTI, Kidney, Maryland School, Immune system, Clinical trial, Therapy, Quality of life, Pelvic floor dysfunction, Pharmaceutical industry

Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.

Key Points: 
  • Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced today.
  • The South Korean patent was granted on Makana’s Triple Knockout pig, or “TKO,” which is a combination of three xenoantigen gene knockouts in the pig that effectively camouflage the cross-species grafts from the human recipient’s immune system.
  • Platt added, “The Triple Knockout Pig has fundamentally changed the field and has moved xenotransplantation closer to becoming a clinically available reality.
  • “The TKO pig is widely seen as the preferred genetic profile that will enter clinical trials,” Platt said.

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

Retrieved on: 
星期二, 四月 30, 2024
Software, Research, Optical, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, FDA, Other Science, Health, Diabetes, Health policy, Nephrology, Kidney disease, Patient, Disorder, Population health, System, National Kidney Foundation, Risk, AI, Food, Kidney failure, Death, Health care, Breakthrough, Disease, CKD, Retina, Eye, Developed country, Kidney transplantation, Dialysis, Microangiopathy, Medicare, Multimedia, Chronic kidney disease, Overalls, Pharmaceutical industry

Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology.
  • MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes.
  • Toku developed MyKidneyAI to help identify individuals with diabetes who have elevated CKD risk via a simple eye exam available in eye care or primary care settings.
  • FDA's Breakthrough designation expedites the review process, shortening the time until technology reaches patients if cleared by the FDA.

The National Kidney Foundation Urges Passage of New Home Dialysis Bill

Retrieved on: 
星期二, 四月 23, 2024
Education, Congress, Patient, National Kidney Foundation, Kidney, Transplant, Travel, Disability, Health, House, Employment, Kidney disease, Senate, Renal replacement therapy, Nursing, ESKD, Legislation, Dialysis, Earl Blumenauer, Crash, Quality of life, NKF

WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis. The Improving Access to Home Dialysis Act (HR-8075) was introduced today in the U.S. House of Representatives by Reps. Carol Miller (R-WV), Marilyn Strickland (D-WA), Earl Blumenauer (D-OR), and Mariannette Miller-Meeks (R-IA). A companion bill is expected to be introduced soon in the Senate.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- The National Kidney Foundation is applauding a move by Congress to increase access to care and improve outcomes for some patients on dialysis.
  • Home dialysis is a form of renal (kidney) replacement therapy (aka, dialysis) that can be done at home by the patient alone or with the help of a care partner.
  • "Patients deserve to know about all options for dialysis so they can make an educated choice for themselves," said Kevin Longino, Chief Executive Officer of the National Kidney Foundation and a kidney transplant recipient.
  • "Policies like this make me increasingly optimistic that more kidney patients struggling with dialysis can have a chance to get some of their life back."

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期四, 三月 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

HHS Technology Group Introduces ConstellationAI to Power Healthcare Digital Asset Discovery with Artificial Intelligence

Retrieved on: 
星期二, 四月 2, 2024
Harness, COVID-19, National Kidney Foundation, Constellation, AI, HTG, Heart, Creativity, Federated, Cryptocurrency

FORT LAUDERDALE, Fla., April 2, 2024 /PRNewswire/ -- HHS Technology Group, LLC™ (HTG) announced today that it has introduced ConstellationAI, an artificial intelligence-driven healthcare digital asset marketplace that holds the potential to catalyze discovery, drive innovation, and unlock hidden value.

Key Points: 
  • FORT LAUDERDALE, Fla., April 2, 2024 /PRNewswire/ -- HHS Technology Group, LLC™ (HTG) announced today that it has introduced ConstellationAI , an artificial intelligence-driven healthcare digital asset marketplace that holds the potential to catalyze discovery, drive innovation, and unlock hidden value.
  • With ConstellationAI, users can discover and connect different digital assets leveraging an advanced studio for model development and federated asset discovery.
  • By seamlessly integrating state-of-the-art AI capabilities with a unique federated asset discovery methodology, we are delivering unparalleled efficiency, productivity, and results."
  • ConstellationAI leverages the power of HTG's revolutionary data platform, Discover your Data® (DyD®), alongside cutting-edge AI technology to help researchers unlock unparalleled insights and opportunities.